INTS Intensity Therapeutics Inc Com

  0%
Previous Close
Open
52 Week Low
52 Week High
Market Cap $0
Shares 17,594,053
Float 10,683,533
Enterprise Value $0
Volume 0
Av. Daily Volume 0
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
INT230-6 (VINblastine CIsplatin) - INVINCIBLE
Early-stage presurgical breast cancer
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
INT230-6 with Keytruda
Pancreatic, Colon, Bile Duct and Squamous Cell Cancer
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
INT230-6 in combination with Yervoy
Triple Negative Breast Cancer, Sarcomas, Hepatic Cancers
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
INT230-6-6mTNBC
Triple Negative Breast Cancer
Phase 2/3
Phase 2/3
Phase 2/3 FDA has reviewed development plan for this indication study which is expected to start 2022.
INT230-6
Advanced Soft Tissue Sarcoma
Phase 2
Phase 2
Phase 2 trial ongoing, noted December 7, 2021. Phase 3 expected to initiate 2H 2022.